🍽️ fluvastatin sodium salt,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Lowering Cholesterol: Fluvastatin belongs to a class of medications known as statins, which work by inhibiting the enzyme HMG-CoA reductase involved in cholesterol synthesis. By reducing cholesterol production in the liver, fluvastatin helps lower levels of low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol.

  2. Reducing Triglycerides: In addition to lowering LDL cholesterol, fluvastatin may also have a modest effect on reducing triglyceride levels, another type of fat in the blood that can contribute to cardiovascular risk when elevated.

  3. Increasing High-Density Lipoprotein (HDL) Cholesterol: Fluvastatin may also help increase levels of high-density lipoprotein (HDL) cholesterol, often referred to as "good" cholesterol. HDL cholesterol is beneficial because it helps remove excess cholesterol from the bloodstream and transport it to the liver for excretion.

  4. Preventing Cardiovascular Events: By effectively lowering cholesterol levels, especially LDL cholesterol, fluvastatin helps reduce the risk of cardiovascular events such as heart attacks, strokes, and coronary artery disease in individuals with or at high risk for cardiovascular disease.

  5. Management of Atherosclerosis: Atherosclerosis is a condition characterized by the buildup of plaque (composed of cholesterol, fat, and other substances) in the arteries, leading to narrowing and hardening of the arteries. Fluvastatin, by lowering cholesterol levels, can slow down the progression of atherosclerosis and reduce the risk of complications associated with this condition.

  6. Primary Prevention: Fluvastatin may be prescribed for primary prevention in individuals with moderate to high cardiovascular risk factors but without established cardiovascular disease. It can help lower the risk of developing cardiovascular events in these individuals.

  7. Secondary Prevention: Fluvastatin is also used for secondary prevention in individuals with established cardiovascular disease, such as those who have previously experienced a heart attack, stroke, or other cardiovascular events. It helps reduce the risk of recurrent events and improves overall cardiovascular outcomes.

  8. Dosage Forms: Fluvastatin is available in various formulations, including immediate-release tablets, extended-release tablets, and sustained-release capsules, to provide flexibility in dosing and optimize cholesterol-lowering effects.

  9. Side Effects: Common side effects of fluvastatin may include muscle pain or weakness (myalgia), gastrointestinal disturbances (such as nausea, diarrhea, or constipation), headache, dizziness, and elevated liver enzymes. Rare but serious side effects may include muscle breakdown (rhabdomyolysis) and liver damage.

  10. Drug Interactions: Fluvastatin may interact with other medications, including certain antibiotics, antifungal agents, immunosuppressants, and drugs metabolized by the cytochrome P450 system. It is important to inform healthcare providers about all medications, supplements, and herbal products being taken to avoid potential interactions.

  11. Monitoring: Patients taking fluvastatin may require regular monitoring of cholesterol levels, liver function tests, and muscle symptoms. Adjustments to the dosage or discontinuation of the medication may be necessary based on treatment response and tolerability.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of fluvastatin sodium salt,(prescription) On Probiotics

Rank Probiotic Impact
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by fluvastatin sodium salt,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Escherichia genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Bifidobacterium genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Dorea genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Lacticaseibacillus genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Phocaeicola genus Decreases 👪 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Bifidobacterium adolescentis species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Collinsella aerofaciens species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Bilophila wadsworthia species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of fluvastatin sodium salt,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0 0
Acne 0.3 -0.3
ADHD 2 2
Age-Related Macular Degeneration and Glaucoma 0.2 0.1 1
Allergic Rhinitis (Hay Fever) 0.9 1.3 -0.44
Allergies 3.2 1.4 1.29
Allergy to milk products 1.4 0.7 1
Alopecia (Hair Loss) 0.8 0.8
Alzheimer's disease 2.3 1.4 0.64
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.3 1 0.3
Ankylosing spondylitis 2.5 0.6 3.17
Anorexia Nervosa 0.1 0.8 -7
Antiphospholipid syndrome (APS) 1.1 0 0
Asthma 0.6 0.1 5
Atherosclerosis 0.9 0.4 1.25
Atrial fibrillation 1.2 0.9 0.33
Autism 4 3.5 0.14
Barrett esophagus cancer 0.4 0.1 3
benign prostatic hyperplasia 0.4 0.4
Biofilm 1.8 1.8
Bipolar Disorder 0.7 0.2 2.5
Brain Trauma 0.5 0.1 4
Cancer (General) 0 1.9 0
Carcinoma 1.7 1.2 0.42
Celiac Disease 1.2 1.4 -0.17
Cerebral Palsy 0.8 0.3 1.67
Chronic Fatigue Syndrome 3 2 0.5
Chronic Kidney Disease 0.6 0.4 0.5
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 1 0.1 9
Chronic Urticaria (Hives) 1.9 0.1 18
Coagulation / Micro clot triggering bacteria 1.4 0.4 2.5
Colorectal Cancer 2.9 0.5 4.8
Constipation 0.7 0.2 2.5
Coronary artery disease 0.4 0.3 0.33
COVID-19 5.8 4 0.45
Crohn's Disease 4.1 2 1.05
cystic fibrosis 1.3 0.3 3.33
deep vein thrombosis 1.3 0.2 5.5
Depression 4.3 2.8 0.54
Dermatomyositis 0.1 0.3 -2
Eczema 0.6 0.9 -0.5
Endometriosis 2.1 0.4 4.25
Eosinophilic Esophagitis 0.3 0.1 2
Epilepsy 1.7 0.6 1.83
Fibromyalgia 1.1 0.8 0.38
Functional constipation / chronic idiopathic constipation 2.6 0.8 2.25
gallstone disease (gsd) 1.4 0.6 1.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.6 0.4 0.5
Generalized anxiety disorder 1.7 0.9 0.89
giant cell arteritis 0.3 -0.3
Glioblastoma 0.1 -0.1
Graves' disease 0.6 0.6 0
Halitosis 0.5 0.1 4
Hashimoto's thyroiditis 0.7 0.4 0.75
Hidradenitis Suppurativa 0.5 0.1 4
High Histamine/low DAO 1.9 0.4 3.75
hypercholesterolemia (High Cholesterol) 0.4 0.4
hyperglycemia 0.4 0.5 -0.25
Hyperlipidemia (High Blood Fats) 0.5 0.3 0.67
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 1.3 2 -0.54
Hypothyroidism 0.4 -0.4
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 1.2 -1.2
Inflammatory Bowel Disease 2.4 2.2 0.09
Insomnia 0.3 0.2 0.5
Intelligence 0.5 0.5
Intracranial aneurysms 0.4 0.3 0.33
Irritable Bowel Syndrome 2.4 0.9 1.67
Liver Cirrhosis 2.3 1.3 0.77
Long COVID 2.6 4.2 -0.62
Low bone mineral density 0.1 -0.1
Lung Cancer 0.5 0.5 0
Mast Cell Issues / mastitis 0.5 0.4 0.25
ME/CFS with IBS 0.6 1.1 -0.83
ME/CFS without IBS 0.6 1.1 -0.83
Menopause 1.1 1.1
Metabolic Syndrome 3.9 3.1 0.26
Mood Disorders 5.7 2.8 1.04
multiple chemical sensitivity [MCS] 0.3 0.2 0.5
Multiple Sclerosis 1.9 1.9 0
Multiple system atrophy (MSA) 0.4 0.5 -0.25
neuropathic pain 0.3 -0.3
Neuropathy (all types) 0.3 0.4 -0.33
neuropsychiatric disorders (PANDAS, PANS) 0.9 0.9
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.5 2.1 -0.4
NonCeliac Gluten Sensitivity 0.3 -0.3
Obesity 3.1 1.6 0.94
obsessive-compulsive disorder 3.4 0.7 3.86
Osteoarthritis 1.2 0.1 11
Osteoporosis 1.1 0.2 4.5
pancreatic cancer 0.2 0.2
Parkinson's Disease 1.6 1.5 0.07
Polycystic ovary syndrome 1.2 0.9 0.33
Postural orthostatic tachycardia syndrome 0.3 0.3 0
Premenstrual dysphoric disorder 0.7 0.1 6
primary biliary cholangitis 0.2 0.4 -1
Psoriasis 3 0.3 9
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.9 1.7 0.71
Rosacea 0.4 0.3 0.33
Schizophrenia 3.4 0.9 2.78
scoliosis 0.4 -0.4
Sjögren syndrome 1.2 1.7 -0.42
Sleep Apnea 0.8 0.2 3
Slow gastric motility / Gastroparesis 1.2 0.3 3
Small Intestinal Bacterial Overgrowth (SIBO) 1.3 0.2 5.5
Stress / posttraumatic stress disorder 2.1 0.6 2.5
Systemic Lupus Erythematosus 1.4 0.7 1
Tic Disorder 0.2 0.7 -2.5
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 1.1 1.5 -0.36
Type 2 Diabetes 3.6 3 0.2
Ulcerative colitis 2.5 1 1.5
Unhealthy Ageing 2.3 0.3 6.67

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]